Argenx (ARGX) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The phase 3 UplighTED trial (NCT06307626) tested Argenx’s efgartigimod PH20 SC, delivered by prefilled syringe, in adults with active moderate to severe thyroid eye disease. The goal was to see if the drug could safely reduce eye symptoms versus placebo and support a new use case that might broaden Argenx’s autoimmune portfolio.
The study compared subcutaneous efgartigimod PH20 SC, a combination product designed to lower harmful antibodies, with a matching placebo injection. The intent was to offer a convenient, injectable treatment option that could compete with existing biologic therapies for thyroid eye disease and expand real-world use of efgartigimod.
This was a randomized, placebo-controlled, parallel group study where adults were assigned 2:1 to active drug or placebo. Neither patients, doctors, trial staff, nor outcome assessors knew who received which treatment, and the main aim was to test whether efgartigimod improves disease signs and symptoms while remaining safe.
Argenx first submitted the study in March 2024, and the trial was formally stopped on December 15, 2025 after an interim review. The last major update was filed on March 13, 2026, as the company moved into end of study and safety follow up visits, which will complete data collection and inform any final disclosures.
The early termination, due to low chance of meeting the main goal and not for safety reasons, is likely a near term negative for Argenx’s stock as it removes a potential growth driver in thyroid eye disease. It also strengthens the position of rival players in eye and autoimmune drugs and may shift investor focus back to Argenx’s core indications and pipeline risk balance.
The trial is now closed to further treatment but follow up work is still in progress, and investors can track ongoing updates and final results when posted on the ClinicalTrials.gov portal.
To learn more about ARGX’s potential, visit the Argenx drug pipeline page.